Published in Brain Res on September 22, 2007
Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther (2009) 3.33
XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev (2009) 3.03
Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol Ther (2008) 1.57
Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol (2013) 1.23
AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol Ther (2010) 1.22
Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neuroinflammation (2013) 1.21
Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res (2009) 1.20
Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS. PLoS One (2011) 1.14
Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand? Front Neurosci (2010) 1.12
CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit. Mol Ther (2010) 1.08
Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression. Neuropharmacology (2010) 1.04
Motor neuron trophic factors: therapeutic use in ALS? Brain Res Rev (2010) 0.98
Moderate exercise delays the motor performance decline in a transgenic model of ALS. Brain Res (2009) 0.95
Motor neuron-immune interactions: the vicious circle of ALS. J Neural Transm (Vienna) (2010) 0.93
Antioxidant gene therapy against neuronal cell death. Pharmacol Ther (2013) 0.92
Ablation of proliferating cells in the CNS exacerbates motor neuron disease caused by mutant superoxide dismutase. PLoS One (2012) 0.90
Gene delivery to the spinal cord using MRI-guided focused ultrasound. Gene Ther (2015) 0.89
Genetic strategies to study TDP-43 in rodents and to develop preclinical therapeutics for amyotrophic lateral sclerosis. Eur J Neurosci (2011) 0.88
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases. Hum Gene Ther (2016) 0.84
Intraspinal cell transplantation for targeting cervical ventral horn in amyotrophic lateral sclerosis and traumatic spinal cord injury. J Vis Exp (2011) 0.83
Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy. Cent Nerv Syst Agents Med Chem (2012) 0.81
Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application. EPMA J (2010) 0.81
Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis. Glia (2016) 0.79
Sponge-mediated lentivirus delivery to acute and chronic spinal cord injuries. J Control Release (2015) 0.76
MicroNeurotrophins Improve Survival in Motor Neuron-Astrocyte Co-Cultures but Do Not Improve Disease Phenotypes in a Mutant SOD1 Mouse Model of Amyotrophic Lateral Sclerosis. PLoS One (2016) 0.75
αCAR IGF-1 vector targeting of motor neurons ameliorates disease progression in ALS mice. Ann Clin Transl Neurol (2016) 0.75
Potential new complication in drug therapy development for amyotrophic lateral sclerosis. Expert Rev Neurother (2016) 0.75
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 21.65
Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science (1994) 18.08
Onset and progression in inherited ALS determined by motor neurons and microglia. Science (2006) 9.42
Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci (2004) 6.99
ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron (1997) 6.16
An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron (1995) 6.03
Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science (2003) 4.52
Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A (2002) 4.37
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 3.08
Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med (2005) 2.80
Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med (2005) 2.80
Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol (2005) 2.61
Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci (2001) 2.51
From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther (2003) 2.12
Recombinant AAV-mediated gene delivery to the central nervous system. J Gene Med (2004) 1.94
Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci (2000) 1.74
Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J Neurol Sci (2005) 1.74
Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology (1997) 1.70
Signaling by insulin-like growth factor 1 in brain. Eur J Pharmacol (2004) 1.65
Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nat Med (1997) 1.62
Sexual differences in onset of disease and response to exercise in a transgenic model of ALS. Neuromuscul Disord (2003) 1.55
Survival effect of ciliary neurotrophic factor (CNTF) on chick embryonic motoneurons in culture: comparison with other neurotrophic factors and cytokines. J Neurosci (1990) 1.53
A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology (1999) 1.52
Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci (2002) 1.45
IGF-I prevents glutamate-induced motor neuron programmed cell death. Neurobiol Dis (2004) 1.39
A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology (1998) 1.37
Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis. Ann Neurol (2005) 1.36
A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology (1996) 1.33
Neurotrophic agents prevent motoneuron death following sciatic nerve section in the neonatal mouse. J Neurobiol (1994) 1.30
Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med (1996) 1.27
Disease progression of human SOD1 (G93A) transgenic ALS model rats. J Neurosci Res (2006) 1.24
Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of Amyotrophic Lateral Sclerosis. J Neurol Sci (2005) 1.23
Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. Hum Gene Ther (2002) 1.22
Role of insulin-like growth factor I signaling in neurodegenerative diseases. J Mol Med (Berl) (2003) 1.22
Targeted expression of IGF-1 transgene to skeletal muscle accelerates muscle and motor neuron regeneration. FASEB J (2002) 1.14
Sexual dimorphism in disease onset and progression of a rat model of ALS. Amyotroph Lateral Scler (2007) 1.13
Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene Ther (2003) 1.08
Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2. Hum Mol Genet (2000) 1.06
Interaction between interferon gamma and insulin-like growth factor-1 in hippocampus impacts on the ability of rats to sustain long-term potentiation. J Neurochem (2006) 1.03
Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol (1993) 1.02
Preclinical testing of neuroprotective neurotrophic factors in a model of chronic motor neuron degeneration. Neurobiol Dis (1999) 1.01
Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases. Trends Neurosci (1997) 1.00
Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol Res (2005) 0.97
Loss of the astrocyte glutamate transporter GLT1 modifies disease in SOD1(G93A) mice. Exp Neurol (2006) 0.97
Gene-based treatment of motor neuron diseases. Muscle Nerve (2006) 0.94
Prevention of spinal motor neuron death by insulin-like growth factor-1 associating with the signal transduction systems in SODG93A transgenic mice. J Neurosci Res (2005) 0.92
Adeno-associated viral-mediated insulin-like growth factor delivery protects motor neurons in vitro. Neuromolecular Med (2004) 0.90
Protective effects of cardiotrophin-1 adenoviral gene transfer on neuromuscular degeneration in transgenic ALS mice. Hum Mol Genet (2001) 0.89
Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis. Lancet (2003) 0.88
Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke (2006) 0.88
Delayed application of IGF-I and GDNF can rescue already injured postnatal motor neurons. Neuroreport (2001) 0.86
The insulin-like growth factor system in multiple sclerosis. Int Rev Neurobiol (2007) 0.85
Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases. Hum Gene Ther (2000) 0.85
Motoneuron cell death and neurotrophic factors: basic models for development of new therapeutic strategies in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord (2001) 0.84
Gene therapy for ALS delivers. Trends Neurosci (2004) 0.83
Insulin-like growth factor system in amyotrophic lateral sclerosis. Endocr Dev (2005) 0.83
Insulin-like growth factor 1 prevents neuronal cell death and paraplegia in the rabbit model of spinal cord ischemia. J Thorac Cardiovasc Surg (2001) 0.83
Beneficial effects of insulin-like growth factor-I on wobbler mouse motoneuron disease. J Neurol Sci (1995) 0.82
Topical application of insulin like growth factor-1 reduces edema and upregulation of neuronal nitric oxide synthase following trauma to the rat spinal cord. Acta Neurochir Suppl (1997) 0.82
Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system. Mol Ther (2003) 0.81
Rescue of rat spinal motoneurons from avulsion-induced cell death by intrathecal administration of IGF-I and Cerebrolysin. Ann Anat (2003) 0.80
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 18.73
Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature (2005) 7.19
Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature (2012) 4.95
Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science (2003) 4.52
Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A (2002) 4.37
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol (2008) 4.16
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Mechanisms of Disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol (2006) 3.42
Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol (2006) 3.39
RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron (2013) 3.25
NG2+ CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration. Neuron (2010) 3.08
Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci (2013) 2.71
Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci (2008) 2.67
Variations in promoter activity reveal a differential expression and physiology of glutamate transporters by glia in the developing and mature CNS. J Neurosci (2007) 2.53
Presynaptic regulation of astroglial excitatory neurotransmitter transporter GLT1. Neuron (2009) 2.48
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol (2013) 2.43
Spectrin mutations cause spinocerebellar ataxia type 5. Nat Genet (2006) 2.34
RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A (2013) 2.31
Human nasal olfactory epithelium as a dynamic marker for CNS therapy development. Exp Neurol (2011) 2.13
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013) 2.09
Recovery from paralysis in adult rats using embryonic stem cells. Ann Neurol (2006) 1.69
A neuronal glutamate transporter contributes to neurotransmitter GABA synthesis and epilepsy. J Neurosci (2002) 1.69
Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler (2012) 1.62
Glutamate transporters: animal models to neurologic disease. Neurobiol Dis (2004) 1.62
Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol (2002) 1.61
Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol (2006) 1.60
A targeted neuroglial reporter line generated by homologous recombination in human embryonic stem cells. Stem Cells (2009) 1.59
Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol (2002) 1.52
Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress. J Clin Invest (2009) 1.51
Molecular comparison of GLT1+ and ALDH1L1+ astrocytes in vivo in astroglial reporter mice. Glia (2011) 1.49
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol (2006) 1.46
Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats. Proc Natl Acad Sci U S A (2004) 1.45
Motor neuron disease occurring in a mutant dynactin mouse model is characterized by defects in vesicular trafficking. J Neurosci (2008) 1.45
Reality and immortality--neural stem cells for therapies. Nat Biotechnol (2004) 1.44
Viral-induced spinal motor neuron death is non-cell-autonomous and involves glutamate excitotoxicity. J Neurosci (2004) 1.40
Loss of beta-III spectrin leads to Purkinje cell dysfunction recapitulating the behavior and neuropathology of spinocerebellar ataxia type 5 in humans. J Neurosci (2010) 1.39
Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120. Virology (2003) 1.39
Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo. Proc Natl Acad Sci U S A (2011) 1.38
Amyotrophic lateral sclerosis: pathogenesis, differential diagnoses, and potential interventions. J Spinal Cord Med (2002) 1.38
Mechanisms for reversible regulation between G13 and Rho exchange factors. J Biol Chem (2001) 1.37
Regulation of astrocytic glutamate transporter expression by Akt: evidence for a selective transcriptional effect on the GLT-1/EAAT2 subtype. J Neurochem (2006) 1.35
Messenger RNA oxidation occurs early in disease pathogenesis and promotes motor neuron degeneration in ALS. PLoS One (2008) 1.34
Astrocyte glutamate transporters regulate metabotropic glutamate receptor-mediated excitation of hippocampal interneurons. J Neurosci (2004) 1.31
Human embryonic germ cell derivatives facilitate motor recovery of rats with diffuse motor neuron injury. J Neurosci (2003) 1.31
Exome sequencing to identify de novo mutations in sporadic ALS trios. Nat Neurosci (2013) 1.31
Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells. J Biol Chem (2004) 1.30
Signal-crosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II. Arterioscler Thromb Vasc Biol (2005) 1.27
Adult glial precursor proliferation in mutant SOD1G93A mice. Glia (2008) 1.27
The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct? Exp Neurol (2002) 1.27
Epigenetic regulation of neuron-dependent induction of astroglial synaptic protein GLT1. Glia (2010) 1.25
Selective up-regulation of the glial Na+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in neuroprotection. Neurobiol Dis (2005) 1.23
Insulin growth factor-1 gene transfer enhances neurovascular remodeling and improves long-term stroke outcome in mice. Stroke (2008) 1.22
Climbing fiber activation of EAAT4 transporters and kainate receptors in cerebellar Purkinje cells. J Neurosci (2004) 1.21
Neural stem cells protect against glutamate-induced excitotoxicity and promote survival of injured motor neurons through the secretion of neurotrophic factors. Mol Cell Neurosci (2004) 1.20
Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One (2013) 1.19
Localization of a toxic form of superoxide dismutase 1 protein to pathologically affected tissues in familial ALS. Proc Natl Acad Sci U S A (2012) 1.17
Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Mol Ther (2003) 1.17
Degeneration of respiratory motor neurons in the SOD1 G93A transgenic rat model of ALS. Neurobiol Dis (2005) 1.16
Glutamate receptor antagonists protect from virus-induced neural degeneration. Ann Neurol (2004) 1.16
Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann Neurol (2004) 1.16
Oligodendroglia: metabolic supporters of axons. Trends Cell Biol (2013) 1.15
AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis (2007) 1.15
Reticulon RTN2B regulates trafficking and function of neuronal glutamate transporter EAAC1. J Biol Chem (2007) 1.14
Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS. PLoS One (2011) 1.14
Respiratory impairment in a mouse model of amyotrophic lateral sclerosis. J Appl Physiol (1985) (2006) 1.14
The glutamate-aspartate transporter GLAST mediates glutamate uptake at inner hair cell afferent synapses in the mammalian cochlea. J Neurosci (2006) 1.13
Amyotrophic lateral sclerosis 2-deficiency leads to neuronal degeneration in amyotrophic lateral sclerosis through altered AMPA receptor trafficking. J Neurosci (2006) 1.13
Potential target genes of EMX2 include Odz/Ten-M and other gene families with implications for cortical patterning. Mol Cell Neurosci (2006) 1.12
Multimodal actions of neural stem cells in a mouse model of ALS: a meta-analysis. Sci Transl Med (2012) 1.10
Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery (2009) 1.10
Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord (2007) 1.10
The blood-brain barrier: an engineering perspective. Front Neuroeng (2013) 1.09
Regulation of the glutamate transporter EAAT1 by the ubiquitin ligase Nedd4-2 and the serum and glucocorticoid-inducible kinase isoforms SGK1/3 and protein kinase B. J Neurochem (2003) 1.08
TDP-43 in amyotrophic lateral sclerosis: pathophysiology or patho-babel? Ann Neurol (2007) 1.07
A novel secretory factor, Neurogenesin-1, provides neurogenic environmental cues for neural stem cells in the adult hippocampus. J Neurosci (2003) 1.06
Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther (2007) 1.06
Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression. Neuropharmacology (2010) 1.04
Electrical impedance myography correlates with standard measures of ALS severity. Muscle Nerve (2013) 1.03
β-III spectrin is critical for development of purkinje cell dendritic tree and spine morphogenesis. J Neurosci (2011) 1.03
Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann Neurol (2003) 1.02
Fas/tumor necrosis factor receptor death signaling is required for axotomy-induced death of motoneurons in vivo. J Neurosci (2003) 1.02
Selective ablation of proliferating astrocytes does not affect disease outcome in either acute or chronic models of motor neuron degeneration. Exp Neurol (2008) 1.02
Neuronal activity regulates glutamate transporter dynamics in developing astrocytes. Glia (2011) 1.01
Zones of enhanced glutamate release from climbing fibers in the mammalian cerebellum. J Neurosci (2010) 0.98